BR0308976A - Terapia combinada contra tumores compreendendo derivados de acriloil distamicina substituìda e radioterapia - Google Patents

Terapia combinada contra tumores compreendendo derivados de acriloil distamicina substituìda e radioterapia

Info

Publication number
BR0308976A
BR0308976A BR0308976-2A BR0308976A BR0308976A BR 0308976 A BR0308976 A BR 0308976A BR 0308976 A BR0308976 A BR 0308976A BR 0308976 A BR0308976 A BR 0308976A
Authority
BR
Brazil
Prior art keywords
radiotherapy
acrylamoyl
substituted
combination therapy
distamycin derivatives
Prior art date
Application number
BR0308976-2A
Other languages
English (en)
Inventor
Maria Cristina Rosa Geroni
Jennifer Margaret Tursi
Camilla Fowst
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Publication of BR0308976A publication Critical patent/BR0308976A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)

Abstract

"TERAPIA COMBINADA CONTRA TUMORES COMPREENDENDO DERIVADOS DE ACRILOIL DISTAMICINA SUBSTITUìDA E RADIOTERAPIA". A presente invenção refere-se ao uso de derivados de acriloil distamicina, em particular derivados de <244>-bromo- ou <244>-cloro-acriloil-distamicina em combinação com radioterapia.
BR0308976-2A 2002-04-02 2003-03-17 Terapia combinada contra tumores compreendendo derivados de acriloil distamicina substituìda e radioterapia BR0308976A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02076240 2002-04-02
PCT/EP2003/003192 WO2003082267A1 (en) 2002-04-02 2003-03-17 Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and radiotherapy

Publications (1)

Publication Number Publication Date
BR0308976A true BR0308976A (pt) 2005-01-11

Family

ID=28459529

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0308976-2A BR0308976A (pt) 2002-04-02 2003-03-17 Terapia combinada contra tumores compreendendo derivados de acriloil distamicina substituìda e radioterapia

Country Status (19)

Country Link
US (1) US20110166077A9 (pt)
EP (1) EP1490053B1 (pt)
JP (1) JP2005527552A (pt)
KR (1) KR100968657B1 (pt)
CN (1) CN1302777C (pt)
AT (1) ATE383154T1 (pt)
AU (1) AU2003219102B2 (pt)
BR (1) BR0308976A (pt)
CA (1) CA2481005C (pt)
DE (1) DE60318561T2 (pt)
ES (1) ES2299692T3 (pt)
IL (2) IL164356A0 (pt)
MX (1) MXPA04009542A (pt)
NO (1) NO20044709L (pt)
NZ (1) NZ535700A (pt)
PL (1) PL373998A1 (pt)
RU (1) RU2314807C2 (pt)
WO (1) WO2003082267A1 (pt)
ZA (1) ZA200407948B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0015446D0 (en) * 2000-06-23 2000-08-16 Pharmacia & Upjohn Spa Combined therapy against tumors comprising substituted acryloyl distamycin derivates,taxanes and/or antimetabolites
MXPA05009851A (es) * 2003-03-18 2005-12-06 Pharmacia Italia Spa Como radiosensibilizador en combinacion con terapia con radiacion contra tumores.
PL1868599T3 (pl) * 2005-04-08 2010-04-30 Nerviano Medical Sciences Srl Przeciwnowotworowa kombinacja zawierająca podstawione akryloilowe pochodne dystamycyny oraz przeciwciała hamujące czynniki wzrostu lub ich receptory
RU2478374C1 (ru) * 2012-02-06 2013-04-10 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Минздравсоцразвития России Способ внутриполостной терапии при лечении больных с метастазами рака во влагалище

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990012321A1 (en) * 1989-03-31 1990-10-18 The Cancer Institute Board Halogenated dna ligand radiosensitisers for cancer therapy
JPH0925268A (ja) * 1995-07-12 1997-01-28 Taiho Yakuhin Kogyo Kk 2−ニトロイミダゾール誘導体
GB9615692D0 (en) * 1996-07-25 1996-09-04 Pharmacia Spa Acryloyl substituted distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents
US6331286B1 (en) * 1998-12-21 2001-12-18 Photogen, Inc. Methods for high energy phototherapeutics
WO1999060023A1 (en) * 1998-05-15 1999-11-25 Imclone Systems Incorporated Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
US6498181B1 (en) * 1999-01-06 2002-12-24 Maxim Pharmaceuticals Synergistic tumorcidal response induced by histamine
US6576759B2 (en) * 1999-02-10 2003-06-10 Pangene Corporation Antisense inhibition of RAD51
GB0011059D0 (en) * 2000-05-08 2000-06-28 Pharmacia & Upjohn Spa Use of substituted acryloyl distamycin derivatives in the treatment of tumours associated with high levels of glutathione
GB0015447D0 (en) * 2000-06-23 2000-08-16 Pharmacia & Upjohn Spa Combined therapy against tumors comprising substituted acryloyl derivates and alkylating agents
US6576612B1 (en) * 2000-10-02 2003-06-10 Pharmacia Italia S.P.A. Antitumor therapy comprising distamycin derivatives

Also Published As

Publication number Publication date
ATE383154T1 (de) 2008-01-15
ZA200407948B (en) 2006-08-30
KR20040101379A (ko) 2004-12-02
HK1079116A1 (en) 2006-03-31
CN1649583A (zh) 2005-08-03
IL164356A0 (en) 2005-12-18
US20110166077A9 (en) 2011-07-07
RU2004131860A (ru) 2005-04-10
KR100968657B1 (ko) 2010-07-06
MXPA04009542A (es) 2005-01-25
PL373998A1 (en) 2005-09-19
CA2481005C (en) 2009-06-09
EP1490053B1 (en) 2008-01-09
US20050143315A1 (en) 2005-06-30
AU2003219102A1 (en) 2003-10-13
WO2003082267A1 (en) 2003-10-09
IL164356A (en) 2010-11-30
AU2003219102B2 (en) 2008-05-08
NO20044709L (no) 2004-12-30
DE60318561D1 (de) 2008-02-21
DE60318561T2 (de) 2009-01-08
CN1302777C (zh) 2007-03-07
RU2314807C2 (ru) 2008-01-20
ES2299692T3 (es) 2008-06-01
JP2005527552A (ja) 2005-09-15
EP1490053A1 (en) 2004-12-29
CA2481005A1 (en) 2003-10-09
NZ535700A (en) 2007-06-29

Similar Documents

Publication Publication Date Title
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
TW200612918A (en) Lonidamine analogs
AP1913A (en) Substituted benzazoles and use thereof as raf kinase inhibitors
TW200501960A (en) Synergistic kits and compositions for treating cancer
EP2267454A3 (en) Diagnosis and prevention of cancer cell invasion
DK1373215T3 (da) Gelanamycinderivater egnet til behandling af cancer
WO2002046477A3 (en) Endogenous retroviruses up-regulated in prostate cancer
IT1333697B (pt)
MY138059A (en) Use of ikb-kinase inhibitors in pain therapy
WO2004064727A3 (en) Method of cancer treatment using hdac inhibitors
IL174965A0 (en) SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF Raf KINASE
MXPA05012421A (es) Tratamiento sinergistico de cancer usando inmunomeros junto con agentes quimioterapeuticos.
AU2003205077A1 (en) Imaging agents and methods of imaging naaladase of psma
DE60037394D1 (de) VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
WO2004037341A3 (en) Method and device for treating concer with electrical therapy in conjunction with chemotherapeutic agents and radiation therapy
NO20014560L (no) Quinasoliner og terapautisk anvendelse derav
DE50310516D1 (de) Fredericamycin-derivate
GB0121490D0 (en) Ciompounds
WO2003028629A3 (en) Chlorin photosensitizing agents for use in photodynamic therapy
MXPA04007443A (es) Nuevos compuestos de porfirina-platino solubles en agua con alta selectividad tumoral y su uso para el tratamiento de enfermedades tumorales benignas y malignas.
IS5570A (is) Meðhöndlun á risaeitlingasarkmeini með tálmum viðeitilfrumueiturslóðinni
GB0121494D0 (en) Compounds
TR200102557T2 (tr) Tiazonlindolinon bileşikleri.
IL164356A0 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and radiotherapy
NO20053903D0 (no) Nukleotidlipidesterderivater.

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: PFIZER ITALIA S.R.L. (IT)

Free format text: TRANSFERIDO POR FUSAO DE: PHARMACIA ITALIA SPA

B25A Requested transfer of rights approved

Owner name: NERVIANO MEDICAL SCIENCE S.R.L. (IT)

Free format text: TRANSFERIDO DE: PFIZER ITALIA S.R.L.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 9A, 10A E 11A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2258 DE 15/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 9A, 10A, 11A, 12A, 13A, 14A, 15A, 16A E 17A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.